Complejo Hospitalario de Salamanca Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04649060
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Complejo Hospitalario de Salamanca

Active Ingredients

Drugs in Phase 3 Trials (3)

daratumumab (darzalex) (1 trial)

dexamethasone (1 trial)

melphalan-flufenamide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3